Version June 2024
| Drug | Route of administration | Typical starting dose | Notes |
| Etanercept | SUBQ | 50 mg SUBQ once weekly | For concurrent moderate to severe plaque psoriasis – Start with etanercept 50 mg twice weekly for 3 months |
| Infliximab | IV | 5 mg/kg IV at 0, 2, and 6 weeks, then every 8 weeks | Administration with a conventional DMARD (eg, methotrexate) promotes drug survival In the United States, SUBQ administration is approved only for ulcerative colitis and Crohn disease, and induction strategy differs; refer to local prescribing information for additional information including approved uses |
| SUBQ[1,2] | SUBQ induction – 120 mg SUBQ once weekly for 5 doses (ie, weeks 0, 1, 2, 3, 4), then 120 mg SUBQ once every 2 weeks IV induction – 3 mg/kg IV at 0 and 2 weeks, then 120 mg SUBQ every 2 weeks starting 4 weeks after the second IV dose | ||
| Adalimumab | SUBQ | 40 mg SUBQ every other week | Administration with a conventional DMARD (eg, methotrexate) promotes drug survival |
| Certolizumab pegol | SUBQ | 400 mg SUBQ at 0, 2, and 4 weeks, followed by 200 mg every other week | PEGylation prevents crossing the placenta |
| Golimumab | SUBQ | 50 mg SUBQ once a month | Available in both SUBQ and IV formulations |
| IV | 2 mg/kg IV at weeks 0 and 4, then every 8 weeks |
With additional data from:
آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟
